{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-035790","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.983412+00:00","generated_at":"2026-06-09T02:47:51.116490+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"C4 Therapeutics discontinues CFT8634 BRD9 degrader; Q3 net loss $27.0M","bullets":["CFT8634 Phase 1 dose escalation failed to show sufficient single-agent efficacy in synovial sarcoma and SMARCB1-null tumors despite high BRD9 degradation; wind-down by Q1 2024.","Net loss $27.0M ($0.55 per share) vs $32.0M ($0.65) in Q3 2022; revenue $11.1M (up from $6.8M) from Roche and Biogen collaborations.","Cash, equivalents and marketable securities $246.4M as of Sept 30, 2023; expected runway into H2 2025.","CFT7455 Phase 1 dose escalation completed in monotherapy for R/R MM; combination arm continues; virtual event on Dec 12, 2023.","Kendra Adams appointed CFO in September 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-035790","json":"https://secwatch.observer/filing/0001628280-23-035790.json","markdown":"https://secwatch.observer/filing/0001628280-23-035790.md","text":"https://secwatch.observer/filing/0001628280-23-035790.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828023035790/0001628280-23-035790-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828023035790/cccc-20231101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T02:47:51.116490+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5bac1dc7400f871f29f60c9962919d4a373ecb84","claim":"C4 Therapeutics, Inc. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On November 1, 2023, C4 Therapeutics, Inc. (the “ Company ”) issued a press release announcing its financial results and business highlights for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662579/000162828023035790/0001628280-23-035790-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}